Skip to content
Screener

AbbVie ABBV Q2 2026 earnings

Reported July 31, 2026 · Before market open

Revenue$17.0BBeat by $185.9M
EPS$3.65Beat by $0.04
Revenue estimate$16.8B
EPS estimate$3.61
“Based on our substantial momentum, AbbVie's long-term outlook remains very strong.”
Robert A. Michael

Earnings data and commentary were extracted with AI from company filings and may contain errors. Verify important details in the filing.

Next report

Oct 30, 2026 (In 3 weeks)
Revenue estimate$17.3B
EPS estimate$3.86

Financials

Q2 2026

Income statement

See full
Revenue$17.0B+10.2%
Gross profit$12.7B+14.6%
Operating income$6.4B+31.4%
Net income$3.6B+285%
EPS (diluted)$2.03+290%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$459.33B+9.9%
P/E72.8×-102×
P/S7.1×+0.1×

Profitability

See full
Gross margin71.5%+0.5pp
Operating margin26.2%—
Net margin9.8%+3.3pp

Segments

By product

See full
Skyrizi$5.5B+24.5%
Rinvoq$2.5B+24.5%
Vraylar$1.1B+19.0%
Botox Therapeutic$1.0B+12.3%
Venclexta$771.0M+11.6%

FAQ

When did AbbVie report Q2 2026 earnings?
AbbVie (ABBV) reported Q2 2026 earnings on July 31, 2026 before market open.
What were AbbVie's Q2 2026 revenue and EPS?
AbbVie reported revenue of $17.0B and eps of $3.65 for Q2 2026.
Did AbbVie beat estimates in Q2 2026?
Revenue beat the consensus estimate of $16.8B by $185.9M. EPS beat the consensus estimate of $3.61 by $0.04.
How did AbbVie's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10.2% from $15.4B a year earlier and eps grew 22.9% from $2.97.
Where can I find AbbVie's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001551152-26-000023) and the 10-Q periodic report (0001551152-26-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.